Source BioScience joins Nottingham precision medicine research alliance

Source BioScience has announced its participation in a Nottingham-based collaboration dedicated to advancing the field of precision medicine.

The company is allying with the University of Nottingham, Nottingham University Hospitals NHS Trust and several industrial partners to launch the Nottingham Molecular Pathology Node for Integrated Multi-platform Biomarker Research and Knowledge Transfer project.

Financially backed by the Medical Research Council and the Engineering and Physical Sciences Research Council, the initiative aims to develop innovative molecular pathology tests to enable superior diagnosis and treatment of disease via a customised approach.

It will bring together informatics, computational modelling and molecular pathology to develop world-leading translational molecular diagnostic capabilities for gastrointestinal, liver and respiratory diseases.

Dr Tom Burr, scientific and technical director at Source BioScience, said: "We are delighted to be part of this groundbreaking research, which will undoubtedly help to realise the potential of personalised medicine."

This comes after the firm recently announced the acquisition of the next-generation sequencing services business from established collaborative partner Oxford Gene Technology.